Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Legend Strategy International Holdings Group Co., Ltd. ( (HK:1355) ) has issued an announcement.
Legend Strategy International Holdings Group Company Limited has completed the acquisition of a 37.5% equity stake in Beisheng Biotechnology via a sale and purchase agreement. The deal, finalized on 6 March 2026 after all conditions precedent were satisfied, expands the group’s investment footprint into the biotechnology sector.
The completed transaction positions Legend Strategy to participate in the growth prospects of Beisheng Biotechnology and signals the group’s continued pursuit of strategic investments. This move may enhance the company’s diversification and could strengthen its standing among investors looking for exposure to biotech-related opportunities.
The most recent analyst rating on (HK:1355) stock is a Hold with a HK$0.13 price target. To see the full list of analyst forecasts on Legend Strategy International Holdings Group Co., Ltd. stock, see the HK:1355 Stock Forecast page.
More about Legend Strategy International Holdings Group Co., Ltd.
Legend Strategy International Holdings Group Company Limited is a Cayman Islands–incorporated company listed in Hong Kong, operating as an investment holding group. The company pursues strategic equity stakes to broaden its portfolio exposure, with a focus on sectors where it can gain meaningful minority positions to support long-term growth.
Average Trading Volume: 449,075
Technical Sentiment Signal: Buy
Current Market Cap: HK$180.2M
For detailed information about 1355 stock, go to TipRanks’ Stock Analysis page.